ArticleOncogene2001
Regulation of the Cdc25A gene by the human papillomavirus Type 16 E7 oncogene.
Article in Oncogene, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis.Viruses · 2021Review
- Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers.Infectious agents and cancer · 2020Review
- SIRT6 inhibits colorectal cancer stem cell proliferation by targeting CDC25A.Oncology letters · 2018Article
- Mechanisms by which HPV Induces a Replication Competent Environment in Differentiating Keratinocytes.Viruses · 2017Review
- The PTPN14 Tumor Suppressor Is a Degradation Target of Human Papillomavirus E7.Journal of virology · 2017Article
- Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein.Cell cycle (Georgetown, Tex.) · 2017Article
- Full-length single-cell RNA-seq applied to a viral human cancer: applications to HPV expression and splicing analysis in HeLa S3 cells.GigaScience · 2015Article
- Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer.British journal of cancer · 2014Article
- The role of Cdc25A in the regulation of cell proliferation and apoptosis.Anti-cancer agents in medicinal chemistry · 2012Review
- Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.The Journal of clinical investigation · 2011Article
- Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity.Journal of lipid research · 2010Article
- Microarray-based analysis of cell-cycle gene expression during spermatogenesis in the mouse.Biology of reproduction · 2010Article
- Human papillomavirus oncoproteins: pathways to transformation.Nature reviews. Cancer · 2010Review
- Oncogenic activities of human papillomaviruses.Virus research · 2009Review
- The human papillomavirus E7 oncoprotein.Virology · 2009Review
- High-risk human papillomavirus type 16 E7 oncogene associates with Cdc25A over-expression in oral squamous cell carcinoma.Virchows Archiv : an international journal of pathology · 2007Article
- Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells.Journal of virology · 2002Article
- Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability.Oncogene · 2002Review
- A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers.Genome research · 2002Article
- Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest.Journal of virology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cdc25A is a tyrosine phosphatase that is involved in the regulation of the G1/S phase transition by activating cyclin E/Cdk2 and cyclin A/Cdk2 complexes through removal of inhibitory phosphorylations. The E6 and E7 oncoproteins of the high-risk human papillomaviruses (HPV) interact with and functionally abrogate the p53 and pRB proteins, respectively. In the present study we have investigated the regulation of the Cdc25A promoter during G1 and S-phases of the cell cycle and by the HPV-16 E7 oncoprotein. Serum induction leads to a derepression of the Cdc25A promoter and can be mediated through two E2F binding sites, E2F-A and E2F-C. While E2F-A is by both E2F1 and E2F4, E2F-C is regulated only by E2F1. The Cdc25A promoter is transactivated by the E7 oncogene of HPV-16. Furthermore, Cdc25A levels are highly increased in E7-expressing cell lines. Inducible expression of E7 leads to an immediate increase in Cdc25A protein levels. These data suggest that Cdc25A may be a critical target of HPV-16 E7 in the disruption of the G1/S phase transition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.